The only FDA-approved biologic enzymatic debridement solution indicated for chronic dermal ulcers and severely burned areas, with a unique mechanism of action to selectively remove necrotic tissue without harming healthy tissue1-3
SANTYL Ointment is the only enzymatic method of debridement shown to uniquely help move wounds toward closure.4,5
Patients who pay more than $20 out of pocket for their prescription, whether they’re insured or not, may be eligible to save with the Copay Assistance Program.
Participants in government healthcare programs or where copay assistance is taxed, restricted, or otherwise prohibited by law are not eligible.
Eligible recipients will pay the first $20; Smith+Nephew will pay the remaining out-of-pocket cost up to the next $220.* The Copay Assistance Card can be used for six prescription fills, up to a $1000 maximum, each year.
For the Hospital Outpatient Department (HOPD) / Qualified Healthcare Professional Office (QHP): Download coding form
For low income patients: Download Patient Assistance Program (PAP) application form
Disclaimer
*This card is the property of IQVIA, and must be returned upon request. Not valid for patients covered under Medicaid, Medicare, or similar state or federal programs. Card is limited to one per person and is not transferable. This card is not health insurance. This offer may be changed or discontinued at any time without notice. Valid at participating pharmacies in the U.S. only, void where taxed, restricted, or prohibited by law. Not valid for prescriptions eligible to be reimbursed under any government program. Information on reimbursement in the U.S. is provided as a courtesy. Due to the rapidly changing nature of the law and the Medicare payment policy, and reliance on information provided by outside sources, the information provided herein does not constitute a guarantee or warranty that reimbursement will be received or that the codes identified herein are or will remain applicable. This information is provided “AS IS” and without any other warranty or guarantee, expressed or implied, as to completeness or accuracy, or otherwise. Providers must confirm or clarify coding and coverage from their respective payers, as each payer may have differing formal or informal coding and coverage policies or decisions. Providers are responsible for accurate documentation of patient conditions and for reporting of products in accordance with particular payer requirements.
**Results are from in vitro studies and are only an approximation of actual therapeutic outcomes. The decision to use a wound care product or combination of products should rest on a clinical judgement in which the perceived benefits outweigh any potential risks.
For detailed product information, including indications for use, contraindications, effects, precautions, warnings, and important safety information, please consult each product's Instructions for Use (IFU) prior to use.
Important Safety Information
Indication: Collagenase SANTYL Ointment (“SANTYL”) is indicated for debriding chronic dermal ulcers and severely burned areas. Contraindications: SANTYL is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase. Warnings and Precautions: The optimal pH range of collagenase is 6 to 8. Higher or lower pH conditions will decrease the enzyme’s activity and appropriate precautions should be taken. The enzymatic activity is also adversely affected by certain detergents, and heavy metal ions such as mercury and silver which are used in some antiseptics. As such, the wound should be properly cleansed prior to application of SANTYL. Debilitated patients should be closely monitored for systemic bacterial infections because of the theoretical possibility that debriding enzymes may increase the risk of bacteremia. A slight transient erythema has been noted occasionally in the surrounding tissue, particularly when SANTYL was not confined to the wound. SANTYL is not indicated for wound closure. Discontinue use of SANTYL after granulation tissue is well-established. Adverse Reactions: No allergic sensitivity or toxic reactions have been noted in clinical use when used as directed. The risk information provided herein is not comprehensive. To see the complete Prescribing Information, please see the FDA-approved product labeling. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.
Recall and Complaints
Customer will provide such support and assistance as S+N may reasonably request in the event of a general or limited voluntary or mandatory recall of the Product(s). Customer shall promptly report any complaint in respect of the Products to complaints@smith-nephew.com.
1. Collagenase SANTYL Ointment [prescribing information]. Fort Worth, TX: Smith & Nephew, Inc.; 2016.
2. Enoch S, et al. Wounds. 2003;15:213-229.
3. Shi L, et al. J Wound Ostomy Continence Nurs. 2009;36(6 Suppl):S12-S16.
4. Motley T A, et al. Advances in wound care, 7(10), 339–348
5. Milne CT, et al. Wounds. 2010;22:270-274.
6. Falanga V. Wounds 2002; 14(2): 47–57.
7. French M, et al. J Protein Chem. 1992;11:83-95.
8. Kim M, et al. Biochim Biophys Acta. 2007;1770:1627-1635.
9. Herman, I. Wounds. 1996; 8:33-40.
10. Riley et al. J Burns Wounds. 2005; 4:112-124.
11. Shi et al. Int Wound J. 2010; 7: 87-95.
12. Sheets AR, et al PLoS ONE 11(7): e0159598.
Text